Coronavirus News and Research

RSS

People may have a pre-existing immune response to COVID-19 thanks to common colds

Now, a new study shows that some people have immune responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, thanks to how the body reacted the last time it caught a cold. This means that even if a person has not been exposed to the novel coronavirus, the body has a memory of it and can trigger an immune response to fight the infection.

10 Aug 2020

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

As the coronavirus vaccine race charges on, many of the investigational candidate vaccines are nearing the final stages of human trials. The results of these trials will determine if they will be granted the green light to manufacture and distribute the vaccine to countries across the globe.

10 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

USA the source of most of New Zealand's coronavirus cases

New Zealand, an island country in the southwestern Pacific Ocean, is marked by its early and fierce determination to totally arrest the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral illness that is causing the current COVID-19 pandemic.

9 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

Community-based sampling needed for COVID-19 control, say researchers

Researchers in the UK have warned that it will be essential to carry out community-based sampling in addition to symptomatic testing if the ongoing transmission of severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) is going to be properly understood and controlled.

9 Aug 2020

New platform shows potential to generate most effective vaccines with fewest side effects

The ongoing COVID-19 pandemic is shining a bright spotlight on vaccine development. As numerous vaccines race through clinical trials, physicians and researchers continue to work on developing new vaccine technologies to generate the most effective vaccines with the fewest side effects.

7 Aug 2020

Swansea University tests new way to give vaccines through microneedle skin patches

A revolutionary new way to give vaccines through microneedle skin patches is being tested at Swansea University, thanks to £200,000 of EU funding announced by the Welsh Government.

7 Aug 2020

Advanced analysis offers new insights into immune system’s role in severe COVID-19

By conducting advanced analyses of immune system activation in patients with severe COVID-19, researchers at Karolinska Institutet have managed to identify several cell types that play a key part in the immune response to the new coronavirus and the hyperinflammation seen in severe cases of the disease.

7 Aug 2020

Your favorite store or restaurant is open. How do you know it’s ok to go in?

Just because many businesses are open again doesn't mean the pandemic is over. The coronavirus is still on the loose — actually surging in many locations — which means people have to make serious choices about their health all day, every day.

7 Aug 2020

In rural Missouri, Latinos learn to contain and cope with the coronavirus

Francisco Bonilla is a pastor in Carthage, Missouri, tending to the spiritual needs of the town’s growing Latino community. He's also a media personality, broadcasting his voice far beyond the walls of Casa de Sanidad. Bonilla runs a low-power, Spanish-language radio station from the church.

7 Aug 2020

Test sites quickly attract thousands for COVID-19 vaccine study

Dr. Eric Coe jumped at the chance to help test a COVID-19 vaccine.

7 Aug 2020

Immunothrombotic dysregulation is key marker of disease severity in COVID-19

In severe cases of COVID-19, the infection can lead to obstruction of the blood vessels in the lung, heart and kidneys. Ludwig-Maximilians-Universitaet (LMU) in Munich researchers have now shown that activated immune cells and blood platelets play a major role in these pathologies.

7 Aug 2020

Coronavirus News and Research

People may have a pre-existing immune response to COVID-19 thanks to common colds

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

USA the source of most of New Zealand's coronavirus cases

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Community-based sampling needed for COVID-19 control, say researchers

New platform shows potential to generate most effective vaccines with fewest side effects

Swansea University tests new way to give vaccines through microneedle skin patches

Advanced analysis offers new insights into immune system’s role in severe COVID-19

Your favorite store or restaurant is open. How do you know it’s ok to go in?

In rural Missouri, Latinos learn to contain and cope with the coronavirus

Test sites quickly attract thousands for COVID-19 vaccine study

Immunothrombotic dysregulation is key marker of disease severity in COVID-19

Coronavirus-specific structure in cells may lead to new antiviral strategies

Study provides detailed insight into problems faced by patients recovering from COVID-19

Oncologists interview physicians to identify specific communication related to COVID-19

Immune system derails during severe course of COVID-19

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News